DYRK1B as therapeutic target in Hedgehog/GLI-dependent cancer cells with Smoothened inhibitor resistance

A wide range of human malignancies displays aberrant activation of Hedgehog (HH)/GLI signaling, including cancers of the skin, brain, gastrointestinal tract and hematopoietic system. Targeting oncogenic HH/GLI signaling with small molecule inhibitors of the essential pathway effector Smoothened (SMO...

Descripción completa

Detalles Bibliográficos
Autores principales: Gruber, Wolfgang, Hutzinger, Martin, Elmer, Dominik Patrick, Parigger, Thomas, Sternberg, Christina, Cegielkowski, Lukasz, Zaja, Mirko, Leban, Johann, Michel, Susanne, Hamm, Svetlana, Vitt, Daniel, Aberger, Fritz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872774/
https://www.ncbi.nlm.nih.gov/pubmed/26784250
http://dx.doi.org/10.18632/oncotarget.6910

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872774/
https://www.ncbi.nlm.nih.gov/pubmed/26784250
http://dx.doi.org/10.18632/oncotarget.6910

Ejemplares similares